Efficacy of Gene Therapy for a Prototypical Lysosomal Storage Disease (GSD-II) Is Critically Dependent on Vector Dose, Transgene Promoter, and the Tissues Targeted for Vector Transduction
Keyword(s):
Keyword(s):
Keyword(s):
2002 ◽
Vol 99
(9)
◽
pp. 5760-5762
◽
Keyword(s):
Keyword(s):
2000 ◽
Vol 23
(3)
◽
pp. 293-298
◽
Keyword(s):
2015 ◽
Vol 114
(2)
◽
pp. 83-93
◽
Keyword(s):